The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Biologics for chronic rhinosinusitis with nasal polyps
Open accessAbstract
With the increasing recognition of the role of type 2 immune responses in chronic rhinosinusitis, its severity, recurrence, and comorbidities, several biologics targeting IL-4, IL-5, and IL-13 as well as IgE have been administered in small proof-of-concept studies. Recently, the first phase 3 trials have been reported with dupilumab, an IL-4 receptor antagonist, demonstrating a significant and clinically relevant reduction of the disease burden from polyp size and sinus involvement to symptoms and smell; these changes consecutively led to an important increase in quality of life. Finally, the biologic versus placebo treatment reduced the need for systemic glucocorticosteroids and sinus surgery significantly and clinically meaningfully. Dupilumab today is registered for the treatment of chronic rhinosinusitis with nasal polyps in Europe and the United States. Within a year, 2 further phase 3 trials with omalizumab and mepolizumab will be reported. With this development, without any doubt, a new era for the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps has begun. Questions on the indication of the biologics, the selection of patients, and finally criteria for monitoring the efficacy in individual patients need to be urgently answered, and care pathways need to be established integrating the current standard of care including surgery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Position Paper on Rhinosinusitis and Nasal Polyps 2020
Fokkens, W. J., Lund, V. J., Hopkins, C., Hellings, P. W., Kern, R., Reitsma, S., Toppila-Salmi, S., Bernal-Sprekelsen, M., Mullol, J., Alobid, I., et al. (2020) · Rhinology journal · doi:10.4193/rhin20.600 · Cited by 5,882
Self-citationBachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794
Self-citationMepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis
Gevaert, P., Van Bruaene, N., Cattaert, T., Van Steen, K., Van Zele, T., Acke, F., De Ruyck, N., Blomme, K., Sousa, A. R., Marshall, R. P., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.07.056 · Cited by 629
Self-citationAkdis, C. A., Bachert, C., Cingi, C., Dykewicz, M. S., Hellings, P. W., Naclerio, R. M., Schleimer, R. P., & Ledford, D. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.02.036 · Cited by 538
Self-citationSoyka, M. B., Wawrzyniak, P., Eiwegger, T., Holzmann, D., Treis, A., Wanke, K., Kast, J. I., & Akdis, C. A. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.05.052 · Cited by 486
Conjunctivitis in dupilumab clinical trials
Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E. L., Blauvelt, A., Cork, M. J., Prens, E., Asbell, P., Akpek, E., Corren, J., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17869 · Cited by 442
Self-citationKohanski, M. A., Workman, A. D., Patel, N. N., Hung, L.-Y., Shtraks, J. P., Chen, B., Blasetti, M., Doghramji, L., Kennedy, D. W., Adappa, N. D., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.03.019 · Cited by 159
Cross-talk between TH2 and TH17 pathways in patients with chronic rhinosinusitis with nasal polyps
Wang, M., Zhang, N., Zheng, M., Li, Y., Meng, L., Ruan, Y., Han, J., Zhao, N., Wang, X., Zhang, L., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.06.023 · Cited by 61
Self-citation
Cited by
Han, J. K., Bachert, C., Fokkens, W., Desrosiers, M., Wagenmann, M., Lee, S. E., Smith, S. G., Martin, N., Mayer, B., Yancey, S. W., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00097-7 · Cited by 628
Self-citationType 2 immunity in allergic diseases
Ogulur, I., Mitamura, Y., Yazici, D., Pat, Y., Ardicli, S., Li, M., D’Avino, P., Beha, C., Babayev, H., Zhao, B., et al. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01261-2 · Cited by 362
Bachert, C., Han, J. K., Wagenmann, M., Hosemann, W., Lee, S. E., Backer, V., Mullol, J., Gevaert, P., Klimek, L., Prokopakis, E., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.11.013 · Cited by 355
Self-citation
Metadata
- Authors
- Bachert, C., Zhang, N., Cavaliere, C., Weiping, W., Gevaert, E., & Krysko, O.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 145
- Issue
- 3
- Pages
- 725-739
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W3009530579
- Cited by
- 199
- References
- 8
- FWCI
- 19.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.